WALTHAM, Mass.--(BUSINESS WIRE)--June 19, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, announced today that David Chaplin, Ph.D., Head of Research and Development and the Company’s Chief Scientific Officer, plans to present at the Second Annual London Biotech Investment Forum at the London Stock Exchange. The London Biotech Investment Forum is a unique one day forum exclusively focusing on promising public and late-stage private companies in the biotechnology industry. Dr. Chaplin is scheduled to present on Thursday, June 22, 2006 at 11:05 a.m. local time in the FORUM room. The London Biotech Investment Forum is not web casting presentations at this conference.
